Aurobindo Pharma Ltd · NSE:AUROPHARMA
Aurobindo Pharma — Q1 FY22 Earnings Presentation
17 slides from Aurobindo Pharma's earnings presentation, Aug 12, 2021
Slide 1: Letter to stock exchanges: Investor/Analysts Presentation
A? AUROBINDO August 12, 2021 To To Listing Department, The Corporate Relations Department NATIONAL STOCK EXCHANGE OF INDIA LIMITED BSE LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), Phiroz Jeejeebhoy Towers, MUMBAI ·400 051 25 th floor, Dalal Street, MUMBAI ·400 001 Company Code No. AUROP
Slide 2: Aurobindo Pharma Limited Earnings Presentation Q1 FY22
Aurobindo Pharma Limited Earnings Presentation Q1 FY22 August 12, 2021
Slide 3: Disclaimer
Disclaimer This presentation is provided for informational purposes only and does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any interest in or securities of Aurobindo Pharma, nor shall it, or any part hereof
Slide 4: Index
Index Q1 FY22 Business & Financial Highlights 01 Financial Performance 02 Filings Snapshot 03 Aurobindo Pharma Limited Earnings Presentation – Q1 FY22
Slide 5: Q1 FY22 Business & Financial Highlights
1 Q1 FY22 Business & Financial Highlights
Slide 6: Consistent Quarterly Performance (Excluding Natrol)
Consistent Quarterly Performance (Excluding Natrol) Revenue (INR Cr) US Revenue ($ Mn) 5,886 6,069 6,065 6,007 5,540 5,702 376 361 374 390 393 364 Q4FY20 Q1FY21 Q2FY21 Q3FY21 Q4FY21 Q1FY22 Q4FY20 Q1FY21 Q2FY21 Q3FY21 Q4FY21 Q1FY22 EBITDA (INR Cr) Net Debt to Equity* 0.16 1,305 1,295 1,281 1,276 1,20
Slide 7: Consolidated Financial Performance (Excluding Natrol) – Q1 FY22
Consolidated Financial Performance (Excluding Natrol) – Q1 FY22 In INR Cr Revenue EBITDA Profit After Tax 2.9% YoY 5.6% YoY 8.9% YoY 1,209 770 5,702 1,146 5,540 707 20.7% 21.2% Q1FY21 Q1FY22 Q1FY21 Q1FY22 Q1FY21 Q1FY22 EBITDA Margin Aurobindo Pharma Limited Earnings Presentation – Q1 FY22
Slide 8: Consolidated Financial & Business Highlights (Excluding Natrol) – Q1 FY22
Consolidated Financial & Business Highlights (Excluding Natrol) – Q1 FY22 Revenue from operations at INR 5,701.9 crore, witnessed a growth of 2.9% YoY Research & Development (R&D) spend at INR 358 crore, 6.3% of revenue EBIDTA before Forex and Other income at INR 1,209.4 crore, an increase of 5.6% Y
Slide 9: US Business Performance Highlights (Excluding Natrol)
US Business Performance Highlights (Excluding Natrol) Revenue (INR Cr) Revenue Mix – Q1FY22 2,862 Orals 2,722 2,681 70.4% Total Injectables Injectables* 24.6% 17.0% Branded Q1FY21 Q4FY21 Q1FY22 Oncology** OTC 7.6% 5.0% US Formulations • US revenue in Q1FY22 declined by 1.5% YoY to Rs. 2,681 crore, a
Slide 10: Europe, ARV, Growth Markets, API Business Performance Highlights
Europe, ARV, Growth Markets, API Business Performance Highlights In INR Cr Europe Revenues Growth Markets Revenues ARV Revenues API Revenues 1,583 329 491 812 1,553 426 794 1,322 780 306 296 290 Q1FY21 Q4FY21 Q1FY22 Q1FY21 Q4FY21 Q1FY22 Q1FY21 Q4FY21 Q1FY22 Q1FY21 Q4FY21 Q1FY22 • Europe revenue in Q
Slide 11: Financial Performance
ed {0 wealthier lite mitt <>
Slide 12: Consolidated Profit & Loss Statement (as reported)
Consolidated Profit & Loss Statement (as reported) INR Cr Q1FY22 Q1FY21 (%) Chg Q4FY21 (%) Chg Revenue from operations 5,702.0 5,924.8 -3.8 6,001.5 -5.0 Gross Profit 3,335.8 3,517.4 -5.2 3,594.4 -7.2 Gross Margin 58.5% 59.4% 59.9% Overheads 2,126.4 2,260.0 -5.9 2,319.7 -8.3 EBITDA (before forex and
Slide 13: Debt Profile
Debt Profile Debt as on (INR Cr) Mar-18 Mar-19 Mar-20 Mar-21 June-21 Fx Loan US$ Mn Closing Rate1 US$ = INR 65.17 69.15 75.66 73.11 74.33 731 1,006 732 674 629 Fx Loan restated in INR 4,766.9 6,959.0 5,549.2 4.928.8 4,675.5 Rupee Loan 4.1 8.1 16.9 43.6 38.4 103 248 Gross Debt 4,771.0 6,967.1 5,566.1
Slide 14: Filing Status
\ \ ‘\ A Mea AUROBNDO Committed to healthier lite
Slide 15: US Filings Snapshot as on 30th June 2021
US Filings Snapshot as on 30th June 2021 ANDA Filings Addressable 451 Therapy ANDAs Market Size 353 (US$ Bn) Non - Injectables 98 Injectables CNS 115 24.2 174 151 CVS 95 27.7 52 29 ARV** 39 4.8 Final Tentative Under Gastroenterological 35 3.4 Approved Awaiting final Approval Approval Review Approved
Slide 16: Global Regulatory Filing details
Global Regulatory Filing details As at As at As at As at As at As at As at As at Jun Category Approvals Mar 15 Mar 16 Mar 17 Mar 18 Mar 19 Mar 20 Mar 21 21 Formulations US* 376 398 429 478 541 586 639 654 480 (FA: 451, TA:29) 2,761 Dossiers (328 Europe** 1,756 2,224 2,521 2,848 3,003 3,214 3,374 3,4
Slide 17: Investors Contact
Investors Contact Investor Relations team ir@aurobindo.com 040-66725401